Enovis Starts Year Strong Despite Integration Impact and Comps

Enovis reported orthopedic sales of $271.5 million in 1Q24, up 59.3 % compared to the first quarter of 2023. As a reminder, we include a portion of Recovery Sciences revenue, reported under Enovis’ Prevention and Recovery business, in our Other segment.

The company’s Reconstructive segment grew 7% on a pro forma basis, including the prior...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us